GlassScriptPhysician profile
Yunsheng Tsai
NPI 1487894747
$2,048.57
in general payments reported to CMS, 2019-2025
18 companies · $841 in 2025
The $841 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.34 · 2023: $689 · 2024: $484 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $488.50 | 2023-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $445.61 | 2022-2025 | |
| Lilly USA, LLC | $246.63 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $165.49 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $136.32 | 2023-2025 | |
| Astellas Pharma US INC | $96.13 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $76.58 | 2023-2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $71.12 | 2023-2024 | Rexulti |
| Amgen INC. | $68.38 | 2024-2025 | Repatha, Otezla, Otezla |
| Gilead Sciences, INC. | $57.83 | 2025 | |
| Axsome Therapeutics, INC. | $52.87 | 2025 | Auvelity |
| Abbott Laboratories | $43.02 | 2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $20.17 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $19.91 | 2023 | Arexvy |
| Abbvie INC. | $16.25 | 2023 | Vraylar |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.39 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $15.11 | 2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.26 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yunsheng Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.